Compare Toronto-Dominion Bank (TD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs Vertex Pharmaceuticals Incorporated — how do they compare? Toronto-Dominion Bank trades at $114.14 (market cap $186.61B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Toronto-Dominion Bank is the larger of the two by market cap, and Toronto-Dominion Bank pays a 2.84% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 84 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TD | VRTX | |
|---|---|---|
Market Cap | $186.61B | $128.16B |
Volume | 4,056,663 | 806,603 |
Sector | Financials | Health |
52-Week High | $124.80 | $557.96 |
52-Week Low | $78.32 | $407.37 |
Typical Hold Time | 84 Days | 120 Days |
Enterprise Value | $559.39B | $122.29B |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD stock trades at $114.04, down 3.5% today, with a bearish technical signal. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.98 versus $1.74 expected. The company announced a $10 billion share buyback program and is expanding its U.S. branch network. Revenue grew to $61.28 billion in 2025, with a net income margin of 24.88%.
The outlook is mixed: strong profitability and analyst buy ratings support upside, but bearish technicals and volatile cash flows pose risks. The stock's valuation appears reasonable with a P/E of 17.39. Key risks include execution of expansion plans and macroeconomic sensitivity.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
